If you enjoy this content, please share it with a colleague
Guided Therapeutics
RELATED CONTENT
August 24, 2016 — Guided Therapeutics Inc. announced in late July that it has sold the first LuViva Advanced Cervical ...
Guided Therapeutics Inc. announced that Nairobi County Health Services Sector has agreed to purchase an additional five LuViva Advanced Cervical Scans for use in the agency’s cervical cancer screening program.
Guided Therapeutics Inc. announced that it has presented the U.S. Food and Drug Administration (FDA) with a plan for advancing the pre-market approval (PMA) application for the LuViva Advanced Cervical Scan. In its “pre-submission” letter, the company also requested a meeting with the agency to finalize the plan.
Guided Therapeutics Inc. announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva Advanced Cervical Scan.
Guided Therapeutics Inc. has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva Advanced Cervical Scan.
April 20, 2012 — Guided Therapeutics Inc. announced this week that the LuViva Advanced Cervical Scan is being introduced to medical leaders at the 40th Anniversary Meeting of the British Society for Colposcopy and Cervical Pathology (BSCCP) in Gateshead, United Kingdom, by Eurosurgical Ltd., the company’s U.K. distributor.
January 3, 2011 — Guided Therapeutics Inc. announced that it was notified by the U.S. Food and Drug Administration (FDA) that the company’s premarket approval application (PMA) for the LightTouch cervical scanner, for patients at risk for cervical cancer, is “suitable for filing.”
October 6, 2009 - The National Cancer Institute (NCI) awarded Guided Therapeutics, Inc. (GT) a $2.5 million matching grant to bring to market and expand the array features for its LightTouch non-invasive cervical cancer detection technology.